Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.
about
Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea.Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea.Fractional calculus in pharmacokinetics.Clinical Practice Guidelines for Irritable Bowel Syndrome in Korea, 2017 Revised Edition.
P2860
Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Optimal dose of ramosetron in ...... ebo-controlled phase II study.
@en
type
label
Optimal dose of ramosetron in ...... ebo-controlled phase II study.
@en
prefLabel
Optimal dose of ramosetron in ...... ebo-controlled phase II study.
@en
P2093
P2860
P356
P1476
Optimal dose of ramosetron in ...... ebo-controlled phase II study.
@en
P2093
K Matsueda
Y Nakashima
P2860
P356
10.1111/NMO.13023
P577
2017-02-16T00:00:00Z